1 completed, 1 not yet recruiting. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Not yet recruiting 1 |
| Phase 1 | 1 | Not yet recruiting 1 |
Follow ILT-101: new trials by email Literature Review of ILT-101 trials Research Report on ILT-101
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Evaluating a Gene Therapy for IPEX Syndrome Through the Expression of FOXP3 on Deficient T Cells to Produce Tregs-like. FOXP3-T4 drug product, ILT-101 - The Immune Dysregulation Polyendocrinopathy Enteropathy X-linked Syndrome is a Primary Immunodeficiency Caused by Pathogenic Variants in Forkhead Box Protein 3 | Phase 1 / Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 5 | 2026-09-01 | 2026-07-13 |
| ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE) ILT-101, Placebo - Systemic Lupus Erythematosus | Phase 2 | Completed | Iltoo Pharma | 100 | 2017-01-18 | 2019-03-05 |
Autoimmune Diseases (1) · Genetic Diseases, Inborn (1) · Lupus Erythematosus, Systemic (1)
Assistance Publique - Hôpitaux de Paris (1) · Iltoo Pharma (1)
France (2) · Austria (1) · Bulgaria (1) · Germany (1) · Italy (1) · Mauritius (1) · Mexico (1) · Portugal (1) · Romania (1) · Spain (1)
2016 (1), 2025 (1)